Biotech columnist Adam Feuerstein responds to biotech stock questions posed by his Twitter followers.
An in-line jobs report is not enough to overcome a weakened consumer, says Professor Peter Morici.
Senior columnist Adam Feuerstein explains why cancer drug stocks are the next big thing in biotech.
E-books are growing in both popularity and sales, but some literary classics are stuck on the shelf.
Here's a look at eight stocks that Paulson & Co. bought in the fourth quarter.
Ranked by endowment, these colleges are putting their vast fortunes toward very different uses.
Cisco welcomes the launch of Apple's new iPad, as well as the slew of Android-based tablets flooding the market.
Starbucks is launching its own single-cup brewer later this year, directly competing with Green Mountain Coffee's Keurig machines.
Stock futures are pointing to a higher open Friday as the February jobs report beat expectations.
Here's a look at 3 shorted stocks that may be too cheap to sell if acquirers weigh bids. (Stocks include FSLR, BBY, VECO)